Published in BMC Cancer on July 02, 2010
The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manag Res (2013) 1.10
Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol (2012) 1.07
Challenges of Pancreatic Cancer. Cancer J (2015) 0.96
Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol (2012) 0.95
Claudin 4 Is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. Int J Mol Sci (2011) 0.91
Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy. Int J Mol Sci (2013) 0.89
Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment. Acta Pharmacol Sin (2011) 0.87
The contribution of cellulosomal scaffoldins to cellulose hydrolysis by Clostridium thermocellum analyzed by using thermotargetrons. Biotechnol Biofuels (2014) 0.82
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer. Int J Cancer (2015) 0.81
Epidermal growth factor modulates claudins and tight junctional functions in ovarian cancer cell lines. Histochem Cell Biol (2012) 0.81
Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers. Toxins (Basel) (2015) 0.79
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. Oncotarget (2015) 0.76
Targeting and alteration of tight junctions by bacteria and their virulence factors such as Clostridium perfringens enterotoxin. Pflugers Arch (2016) 0.76
SCF/C-Kit/JNK/AP-1 Signaling Pathway Promotes Claudin-3 Expression in Colonic Epithelium and Colorectal Carcinoma. Int J Mol Sci (2017) 0.75
Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells. Mol Cancer Ther (2016) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A (2001) 5.57
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res (2000) 3.37
Total synthesis of taxol. Nature (1994) 3.22
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer (2004) 2.26
Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol (1997) 2.25
Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res (2003) 2.01
Coordinately up-regulated genes in ovarian cancer. Cancer Res (2001) 1.93
Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res (2001) 1.83
Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res (2000) 1.81
Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res (2001) 1.77
Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology (2001) 1.75
Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res (2000) 1.32
Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res (2002) 1.29
Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res (2005) 1.28
Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol (2002) 1.15
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch (2007) 1.08
Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res (2007) 1.07
An overview of Clostridium perfringens enterotoxin. Toxicon (1997) 1.04
Measurement of biological activities of purified and crude enterotoxin of Clostridium perfringens. Infect Immun (1975) 0.97
Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog (2003) 0.97
Functional studies on the EGF receptor with an antibody that recognizes the intracellular portion of the receptor. J Biol Chem (1986) 0.92
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. Am J Obstet Gynecol (2009) 0.86
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics (2003) 3.78
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 3.60
A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science (2008) 3.52
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003) 2.44
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer (2004) 2.26
Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A (2007) 2.22
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst (2003) 2.14
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells (2009) 1.84
Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest (2008) 1.82
History of the FIGO cancer staging system. Int J Gynaecol Obstet (2008) 1.81
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol (2007) 1.80
A novel immortalized human endometrial stromal cell line with normal progestational response. Endocrinology (2004) 1.76
Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol (2003) 1.65
Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol (2007) 1.65
Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene (2003) 1.65
Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol (2004) 1.64
Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer (2005) 1.60
Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis (2002) 1.58
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation (2002) 1.57
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol (2012) 1.55
Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol (2009) 1.54
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev (2008) 1.52
Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res (2003) 1.52
Macrophages and apoptotic cell clearance during pregnancy. Am J Reprod Immunol (2004) 1.51
Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. Am J Obstet Gynecol (2004) 1.49
7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: a novel compound capable of inducing cell death in epithelial ovarian cancer stem cells. Cancer Biol Ther (2009) 1.48
Squamous cell carcinoma of the ovary arising from a mucinous cystic tumor of endocervical (müllerian) type. Int J Gynecol Pathol (2010) 1.47
Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res (2003) 1.46
Local injury of the endometrium induces an inflammatory response that promotes successful implantation. Fertil Steril (2010) 1.46
Safe conception for HIV-discordant couples: insemination with processed semen from the HIV-infected partner. Am J Obstet Gynecol (2013) 1.45
HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol Oncol (2003) 1.43
Inflammation and implantation. Am J Reprod Immunol (2010) 1.41
Toll-like receptor-mediated responses by placental Hofbauer cells (HBCs): a potential pro-inflammatory role for fetal M2 macrophages. Am J Reprod Immunol (2014) 1.40
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol (2006) 1.40
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol (2005) 1.40
Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. J Immunol (2010) 1.39
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer (2009) 1.38
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet (2008) 1.38
The role of apoptosis in the regulation of trophoblast survival and differentiation during pregnancy. Endocr Rev (2005) 1.37
Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol (2007) 1.37
High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci (2013) 1.32
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol (2005) 1.31
Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol (2003) 1.31
MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol (2010) 1.29
The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A (2011) 1.29
Activation of TLR3 in the trophoblast is associated with preterm delivery. Am J Reprod Immunol (2009) 1.29
Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther (2011) 1.28
The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.28
Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res (2005) 1.28
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer (2006) 1.27
Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol (2010) 1.27
Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res (2002) 1.27
A role for TLRs in the regulation of immune cell migration by first trimester trophoblast cells. J Immunol (2005) 1.27
Toll-like receptor 4: a potential link between "danger signals," the innate immune system, and preeclampsia? Am J Obstet Gynecol (2005) 1.26
The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol (2008) 1.26
First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. Mol Hum Reprod (2004) 1.25
Placental apoptosis in health and disease. Am J Reprod Immunol (2010) 1.25
Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy disorders. Am J Reprod Immunol (2010) 1.25